Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies von Hing, Z A, Fung, H Y J, Ranganathan, P, Mitchell, S, El-Gamal, D, Woyach, J A, Williams, K, Goettl, V M, Smith, J, Yu, X, Meng, X, Sun, Q, Cagatay, T, Lehman, A M, Lucas, D M, Baloglu, E, Shacham, S, Kauffman, M G, Byrd, J C, Chook, Y M, Garzon, R, Lapalombella, R

Volltext

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia von Rawstron, A C, Villamor, N, Ritgen, M, Böttcher, S, Ghia, P, Zehnder, J L, Lozanski, G, Colomer, D, Moreno, C, Geuna, M, Evans, P A S, Natkunam, Y, Coutre, S E, Avery, E D, Rassenti, L Z, Kipps, T J, Caligaris-Cappio, F, Kneba, M, Byrd, J C, Hallek, M J, Montserrat, E, Hillmen, P

Volltext

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells von Johnson, A J, Yeh, Y-Y, Smith, L L, Wagner, A J, Hessler, J, Gupta, S, Flynn, J, Jones, J, Zhang, X, Bannerji, R, Grever, M R, Byrd, J C

Volltext

Circulating miRNA markers show promise as new prognosticators for multiple myeloma von Rocci, A, Hofmeister, C C, Geyer, S, Stiff, A, Gambella, M, Cascione, L, Guan, J, Benson, D M, Efebera, Y A, Talabere, T, Dirisala, V, Smith, E M, Omedè, P, Isaia, G, De Luca, L, Rossi, D, Gentili, S, Uccello, G, Consiglio, J, Ria, R, Benevolo, G, Bringhen, S, Callea, V, Weiss, B, Ferro, A, Magarotto, V, Alder, H, Byrd, J C, Boccadoro, M, Marcucci, G, Palumbo, A, Pichiorri, F

Volltext

Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells von Mazurek, N, Byrd, J C, Sun, Y, Hafley, M, Ramirez, K, Burks, J, Bresalier, R S

Volltext

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront... von Czuczman, M.S., Leonard, J.P., Jung, S., Johnson, J.L., Hsi, E.D., Byrd, J.C., Cheson, B.D.

Volltext

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells von Zhong, Y, El-Gamal, D, Dubovsky, J A, Beckwith, K A, Harrington, B K, Williams, K E, Goettl, V M, Jha, S, Mo, X, Jones, J A, Flynn, J M, Maddocks, K J, Andritsos, L A, McCauley, D, Shacham, S, Kauffman, M, Byrd, J C, Lapalombella, R

Volltext

The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model von Beckwith, K A, Frissora, F W, Stefanovski, M R, Towns, W H, Cheney, C, Mo, X, Deckert, J, Croce, C M, Flynn, J M, Andritsos, L A, Jones, J A, Maddocks, K J, Lozanski, G, Byrd, J C, Muthusamy, N

Volltext

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse von Braggio, E, Kay, N E, VanWier, S, Tschumper, R C, Smoley, S, Eckel-Passow, J E, Sassoon, T, Barrett, M, Van Dyke, D L, Byrd, J C, Jelinek, D F, Shanafelt, T D, Fonseca, R

Volltext

Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma von Rosko, A, Hofmeister, C, Benson, D, Efebera, Y, Huang, Y, Gillahan, J, Byrd, J C, Burd, C E

Volltext

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL von Brown, J R, Hillmen, P, O’Brien, S, Barrientos, J C, Reddy, N M, Coutre, S E, Tam, C S, Mulligan, S P, Jaeger, U, Barr, P M, Furman, R R, Kipps, T J, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, J M, Munir, T, Burger, J A, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, D F, Byrd, J C

Volltext

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol von Blum, K A, Ruppert, A S, Woyach, J A, Jones, J A, Andritsos, L, Flynn, J M, Rovin, B, Villalona-Calero, M, Ji, J, Phelps, M, Johnson, A J, Grever, M R, Byrd, J C

Volltext

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism von MONE, A. P, CHENEY, C, BANKS, A. L, TRIDANDAPANI, S, MEHTER, N, GUSTER, S, LIN, T, EISENBEIS, C. F, YOUNG, D. C, BYRD, J. C

Volltext

Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism... von Blum, K.A., Jung, S.-H., Johnson, J.L., Lin, T.S., Hsi, E.D., Lucas, D.M., Byrd, J.C., Cheson, B.D., Bartlett, N.L.

Volltext

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: resu... von Byrd, John C., Peterson, Bercedis L., Morrison, Vicki A., Park, Kathleen, Jacobson, Robert, Hoke, Eva, Vardiman, James W., Rai, Kanti, Schiffer, Charles A., Larson, Richard A.

Volltext

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia von Alinari, L, Lapalombella, R, Andritsos, L, Baiocchi, R A, Lin, T S, Byrd, J C

Volltext

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) von Bhatnagar, B, Blachly, J S, Kohlschmidt, J, Eisfeld, A-K, Volinia, S, Nicolet, D, Carroll, A J, Block, A W, Kolitz, J E, Stone, R M, Mrózek, K, Byrd, J C, Bloomfield, C D

Volltext

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells von LUCAS, D. M, DAVIS, M. E, GREVER, M. R, PARTHUN, M. R, MONE, A. P, KITADA, S, CUNNINGHAM, K. D, FLAX, E. L, WICKHAM, J, REED, J. C, BYRD, J. C

Volltext

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity von Byrd, J C, Murphy, T, Howard, R S, Lucas, M S, Goodrich, A, Park, K, Pearson, M, Waselenko, J K, Ling, G, Grever, M R, Grillo-Lopez, A J, Rosenberg, J, Kunkel, L, Flinn, I W

Volltext

Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review von BYRD, J. C, EDENFIELD, W. J, SHIELDS, D. J, DAWSON, N. A

Volltext